Adults with type 2 diabetes who use GLP-1 receptor agonist medications face a modest increase in the risk of developing hair loss, according to a study published by The BMJ on July 22, 2026. Researchers analyzing electronic health records from the University of Pennsylvania Health System found that patients taking drugs like Ozempic, Wegovy, Mounjaro, and Zepbound developed alopecia more frequently than individuals prescribed alternative diabetes treatments, though the overall absolute risk remains low.
Understanding GLP-1 Medications and Alopecia Risk
GLP-1 receptor agonists, which include semaglutide and tirzepatide, have transformed diabetes management and weight loss treatments. However, patient reports of thinning hair have circulated widely. To examine these signals, researchers at Penn Medicine utilized electronic health records to compare alopecia rates among adults starting new therapies between January 2019 and September 2024. The study evaluated 12,004 patients taking GLP-1 receptor agonists against 15,221 patients taking SGLT-2 inhibitors, and a separate cohort of 11,964 GLP-1 users against 11,233 patients taking DPP-4 inhibitors.
Did you know? The Penn Medicine study isolated data from patients across multiple drug classes to establish a clearer comparative risk profile for hair loss.
Comparing Alopecia Rates Across Diabetes Treatments
Before statistical adjustment, patient groups showed distinct demographic and clinical profiles. GLP-1 users had a mean age of 58 and a body mass index (BMI) of 36.2. By contrast, patients taking SGLT-2 inhibitors had a mean age of 65 and a BMI of 32.3, while those on DPP-4 inhibitors averaged 67 years old with a BMI of 31.3. After adjusting for age, sex, ethnicity, pre-existing conditions, concurrent medications, and BMI, the researchers uncovered clear risk differences.
According to the study findings, GLP-1 receptor agonist use was associated with a 37% higher risk of alopecia compared with SGLT-2 inhibitor use, registering 6.91 versus 5.04 cases per 1,000 person-years. When compared against DPP-4 inhibitors, GLP-1 users faced a 68% higher risk, with 6.53 cases per 1,000 person-years compared to 3.89. Further breakdown of the data revealed that this elevated risk was primarily concentrated in non-scarring alopecia—a condition where hair follicles remain intact, preserving the potential for future regrowth.
How Rapid Weight Loss Impacts the Hair Growth Cycle
While the study did not definitively prove a direct physiological pathway, the authors pointed to rapid weight loss as a primary suspect. Substantial weight loss frequently triggers increased hair shedding. Rapid reduction in body weight can also induce temporary iron or zinc deficiencies, both of which are critical micronutrients required to maintain a healthy hair growth cycle. Hormonal fluctuations driven by significant weight reduction or the pharmacological action of the drugs themselves could also contribute to the phenomenon.
Study Limitations and What Remains Unknown
The observational design carries inherent limitations. Clinical records lacked the granular detail needed to evaluate the severity, exact extent, or duration of the alopecia episodes. Furthermore, researchers could not track whether patients experienced hair regrowth after discontinuing the medication. Because the work relied on retrospective electronic health records, it cannot establish direct causation, and unmeasured confounding factors may have influenced the outcomes. Despite these caveats, the study authors characterized their work as rigorous, utilizing high-quality data from a large, representative patient population with consistent results across sensitivity analyses.
Frequently Asked Questions
Do Ozempic and Wegovy cause permanent hair loss?
The study found that the increased risk is primarily tied to non-scarring alopecia, meaning hair follicles remain intact. This suggests a potential for regrowth, though the research did not track long-term recovery outcomes after medication discontinuation.
How much higher is the hair loss risk for GLP-1 users?
Researchers observed a 37% higher risk of alopecia compared to patients taking SGLT-2 inhibitors and a 68% higher risk compared to those on DPP-4 inhibitors, though the absolute risk to individual patients remains low.
Why do GLP-1 medications potentially trigger hair shedding?
Study authors suggest that rapid weight loss—a common result of GLP-1 therapy—often disrupts the normal hair growth cycle and can lead to secondary nutritional deficiencies like low iron or zinc.
Pro Tip: Patients experiencing unexpected hair shedding while managing diabetes or weight loss should consult their primary care physician or endocrinologist to review nutrition levels and treatment options.
To stay informed on the latest clinical research regarding metabolic medications and health outcomes, subscribe to our newsletter or explore our ongoing coverage of pharmaceutical safety studies.
Related reading